Clinical Trial Update: Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study to assess safety and tolerability of AZD2171 (cediranib) after multiple doses in patients with advanced prostate cancer; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Prostate Adenocarcinoma | Phase 1 | Status: COMPLETED